Healthcare Gainers: TherapeuticsMD (NYSEMKT:TXMD), Synta Pharmaceuticals (NASDAQ:SNTA), Cell Therapeutics (NASDAQ:CTIC), Celgene Corporation (NASDAQ:CELG)
On April 7, 2014, TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s healthcare company, announced positive outcomes of a rabbit irritation study for TX 004-HR (formerly referred to as TX 12-004-HR), a rapidly acting estrogen vaginal preparation capsule (VagiCap). TherapeuticsMD Inc (NYSEMKT:TXMD), shares after opening at $4.76 moved to $5.15 on last trade day and at the end of the day closed at $4.93. Company price to sales ratio in past twelve months was calculated as 81.27 and price to cash ratio as 13.20. TherapeuticsMD Inc (NYSEMKT:TXMD), showed a negative weekly performance of 17.42%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company’s Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Synta Pharmaceuticals Corp. (NASDAQ:SNTA), shares advanced 10.07% in last trading session and ended the day on $4.48. Synta Pharmaceuticals Corp. (NASDAQ:SNTA), return on equity ratio is recorded as -231.70% and its return on assets is -112.90%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA), yearly performance is -57.13%.
Cell Therapeutics Inc (NASDAQ:CTIC) got a thumbs up sign from rating agency WallachBeth and Roth Capital during the past few weeks, after the bio tech firm reported solid progress in its full year 2013 and 4Q13 operational results. While WallachBeth, which initiated coverage of this drug firm on 19th March, and recommended a Hold rating on it, Roth Capital had expressed positive outlook for a lead drug candidate called Pacritinib, after a similar drug being manufactured by its competitor Geron had run into rough weather in clinical trial. Cell Therapeutics Inc (NASDAQ:CTIC), shares moved up 6.10% in last trading session and was closed at $3.48, while trading in range of $3.31 – $3.50. Cell Therapeutics Inc (NASDAQ:CTIC), year to date (YTD) performance is 82.20%.
Celgene Corporation (NASDAQ:CELG)’s shares declined 0.68% to $138.22. The company on Mar. 23 released new research findings on OTEZLA (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. Celgene Corporation (NASDAQ:CELG), weekly performance is -0.07%. On last trading day company shares ended up $147.32. Celgene Corporation (NASDAQ:CELG), distance from 50-day simple moving average (SMA50) is -4.11%. Analysts mean target Price for the company is $193.25.